| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
5,660,000 |
| Market
Cap: |
2.49(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4404 - $0.4404 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Graybug Vision is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. Co.'s product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, a potent inhibitor of neovascular growth and permeability, which are causes of retinal disease. Co.'s second product candidate, GB-401, is an intravitreally administered, proprietary implant formulation containing a prodrug of a beta-adrenergic receptor inhibitor developed to provide a controlled release of the active drug to maintain reduced intraocular pressure, for six months or longer after a single injection.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
4,000 |
1,363,274 |
1,505,415 |
1,505,415 |
| Total Buy Value |
$15,600 |
$5,047,430 |
$5,493,543 |
$5,493,543 |
| Total People Bought |
1 |
4 |
7 |
7 |
| Total Buy Transactions |
2 |
6 |
58 |
58 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Orbimed Capital Gp Vi Llc |
10% Owner |
– – • |
2020-09-29 |
4 |
A |
$0.00 |
$0 |
I/I |
3,600,847 |
4,163,347 |
|
- |
|
| Cagle Gerald D. |
Director |
– • – |
2020-09-29 |
4 |
A |
$0.00 |
$0 |
D/D |
3,322 |
3,322 |
|
- |
|
| Keyoung Hansoo Michael |
Director |
– • – |
2020-09-29 |
4 |
A |
$0.00 |
$0 |
I/I |
1,133,596 |
1,133,596 |
|
- |
|
| Shaffer Christy L |
Director |
– • – |
2020-09-29 |
4 |
B |
$16.00 |
$300,000 |
I/I |
18,750 |
1,605,240 |
2.1 |
143% |
|
| Shaffer Christy L |
Director |
– • – |
2020-09-29 |
4 |
A |
$0.00 |
$0 |
I/I |
1,586,490 |
1,586,490 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
10% Owner |
– – • |
2020-09-25 |
4 |
B |
$16.00 |
$9,000,000 |
I/I |
562,500 |
562,500 |
1.5 |
- |
|
131 Records found
|
|
Page 6 of 6 |
|
|
